Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Stephen Harvey Zinner, M.D.

Concepts

This page shows the publications Stephen Zinner has written about Drug Therapy, Combination.
Connection Strength

0.577
  1. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination. Int J Antimicrob Agents. 2004 May; 23(5):451-6.
    View in: PubMed
    Score: 0.130
  2. Predicting antibiotic combination effects on the selection of resistant Staphylococcus aureus: In vitro model studies with linezolid and gentamicin. Int J Antimicrob Agents. 2018 Dec; 52(6):854-860.
    View in: PubMed
    Score: 0.088
  3. Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection. Antimicrob Agents Chemother. 1998 Jan; 42(1):72-7.
    View in: PubMed
    Score: 0.084
  4. Pharmacokinetically-based prediction of the effects of antibiotic combinations on resistant Staphylococcus aureus mutants: in vitro model studies with linezolid and rifampicin. J Chemother. 2017 Aug; 29(4):220-226.
    View in: PubMed
    Score: 0.077
  5. Predicting the antistaphylococcal effects of daptomycin-rifampicin combinations in an in vitro dynamic model. J Antibiot (Tokyo). 2020 02; 73(2):101-107.
    View in: PubMed
    Score: 0.024
  6. Net effect of inoculum size on antimicrobial action of ampicillin-sulbactam: studies using an in vitro dynamic model. Antimicrob Agents Chemother. 1997 Jan; 41(1):7-12.
    View in: PubMed
    Score: 0.019
  7. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother. 1996 May; 40(5):1108-15.
    View in: PubMed
    Score: 0.019
  8. Predictors of effect of ampicillin-sulbactam against TEM-1 beta-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC. Antimicrob Agents Chemother. 1996 Mar; 40(3):734-8.
    View in: PubMed
    Score: 0.018
  9. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother. 1995 Feb; 39(2):445-52.
    View in: PubMed
    Score: 0.017
  10. Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection. J Infect Dis. 1991 Sep; 164(3):499-506.
    View in: PubMed
    Score: 0.013
  11. The antistaphylococcal pharmacodynamics of linezolid alone and in combination with doxycycline in an in vitro dynamic model. J Chemother. 2011 Jun; 23(3):140-4.
    View in: PubMed
    Score: 0.013
  12. Single daily dosing of amikacin in an in-vitro model. J Antimicrob Chemother. 1991 May; 27 Suppl C:15-9.
    View in: PubMed
    Score: 0.013
  13. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med. 1987 12 31; 317(27):1692-8.
    View in: PubMed
    Score: 0.010
  14. In vitro models for the study of combination antibiotic therapy in neutropenic patients. Am J Med. 1986 Jun 30; 80(6B):156-60.
    View in: PubMed
    Score: 0.009
  15. In vitro models in the study of antibiotic therapy of infections in neutropenic patients. Am J Med. 1986 May 30; 80(5C):40-4.
    View in: PubMed
    Score: 0.009
  16. Laboratory support for choosing and monitoring antimicrobial therapy in severely ill patients. Am J Med. 1986 May 30; 80(5C):59-63.
    View in: PubMed
    Score: 0.009
  17. Review of amikacin usage in the EORTC trials. Am J Med. 1985 Jul 15; 79(1A):17-20.
    View in: PubMed
    Score: 0.009
  18. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group. J Infect Dis. 1978 Jan; 137(1):14-29.
    View in: PubMed
    Score: 0.005
  19. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection. Antimicrob Agents Chemother. 1994 Oct; 38(10):2351-6.
    View in: PubMed
    Score: 0.004
  20. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group. Antimicrob Agents Chemother. 1991 May; 35(5):873-8.
    View in: PubMed
    Score: 0.003
  21. Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother. 1986 Feb; 29(2):263-70.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.